Schwab Dividend ETF Boosts Healthcare Exposure With UnitedHealth, Abbott Additions

SCHD has significantly reshuffled its portfolio during its latest annual reconstitution, making strategic moves that enhance the fund's income generation potential while dramatically increasing its exposure to the healthcare sector. The Schwab U.S. Dividend Equity ETF added two major healthcare names—UnitedHealth and Abbott Laboratories—while simultaneously removing AbbVie, a shift that reflects changing valuations and dividend growth trajectories across the healthcare landscape.

For income-focused investors, this reconstitution carries meaningful implications. The newly adjusted portfolio now weights healthcare at 18.9% of total holdings, up significantly from the previous 15.4% allocation. This represents a major strategic pivot toward a sector known for consistent dividend payments and defensive characteristics, positioning SCHD to potentially deliver stronger income streams and total returns going forward.

Key Details of the Portfolio Reshuffle

The reconstitution results reveal important details about how passive index managers evaluate dividend-paying equities:

• Healthcare sector weighting increased from 15.4% to 18.9%—elevating it to the second-largest sector allocation in the fund
• UnitedHealth ($UNH) and Abbott Laboratories ($ABT) were added to the portfolio during the annual rebalancing
• AbbVie ($ABBV) was removed despite being a historically dividend-focused healthcare company
• Average dividend growth rate improved from 8.6% to 9.4% across the fund's holdings

This shift in the portfolio's composition suggests that Schwab's methodology identified stronger dividend growth prospects in UnitedHealth and Abbott compared to AbbVie. Both additions are blue-chip healthcare names with substantial market capitalizations and established track records of returning capital to shareholders. UnitedHealth, as a dominant player in health insurance and healthcare services, and Abbott, with its diversified portfolio spanning diagnostics, medical devices, and nutrition, both offer exposure to secular healthcare growth trends while maintaining robust dividend policies.

The removal of AbbVie is particularly noteworthy, given the company's historical positioning as a dividend aristocrat. This decision likely reflects either a relative decline in AbbVie's dividend growth rate compared to alternatives or a reassessment of the company's competitive positioning and future cash generation capabilities within the index methodology.

Market Context: The Dividend ETF Landscape and Healthcare's Appeal

The SCHD reconstitution occurs within a broader market environment where dividend-focused investing has gained considerable traction. Dividend ETFs like SCHD compete directly with other income-oriented products, including Vanguard Dividend Appreciation ETF (VIG), iShares Select Dividend ETF (DVY), and SPDR S&P Dividend ETF (SDY). Schwab's strategy of emphasizing dividend growth rates—rather than just yield—differentiates the fund in a crowded marketplace.

The increased healthcare weighting reflects several market realities:

• Healthcare sector stability: Healthcare has historically proven resilient during economic downturns, offering defensive characteristics alongside dividend income
• Demographic tailwinds: Aging populations globally continue to drive consistent demand for healthcare products and services
• Regulatory environment: While healthcare faces ongoing regulatory scrutiny, the sector's essential nature provides some insulation from cyclical pressures
• Capital allocation: Major healthcare companies like UnitedHealth and Abbott have demonstrated strong free cash flow generation, enabling consistent dividend increases

The decision to upgrade the portfolio's dividend growth rate—moving from an 8.6% average to 9.4%—signals Schwab's confidence that the newly weighted portfolio can deliver superior income growth over the long term. In an inflationary environment, dividend growth rates matter substantially, as they help shield investors from erosion of purchasing power.

Investor Implications and Total Return Potential

For shareholders in SCHD, these changes carry several important implications:

Enhanced Income Generation: The higher average dividend growth rate suggests the fund should deliver progressively larger dividend payments over time. If the fund maintains its 9.4% average dividend growth rate, investors can expect annual income increases that outpace traditional fixed-income investments and most inflation forecasts.

Sector Concentration and Diversification Trade-off: While the healthcare upgrade to 18.9% weighting improves income potential, it also concentrates the portfolio more heavily in a single sector. Investors should consider whether this level of healthcare exposure aligns with their own portfolio construction and risk tolerance.

Quality Over Yield: SCHD's methodology prioritizes dividend growth rather than current yield alone. This approach historically produces better long-term total returns than high-yield strategies, which often capture companies at mature stages with limited growth prospects. UnitedHealth and Abbott exemplify this philosophy—both are growth-oriented names within healthcare that can compound dividends over time.

Competitive Positioning: The decision to include UnitedHealth and Abbott while removing AbbVie positions SCHD to potentially outperform peer dividend ETFs that may still be overweighted to slower-growing healthcare stalwarts. This tactical adjustment could translate to meaningful relative performance differences over multi-year periods.

Market Timing Considerations: The reconstitution also raises questions about relative valuations. By adding UnitedHealth and Abbott, Schwab is implicitly signaling confidence in their valuations and growth prospects relative to AbbVie. Investors should monitor whether this positioning proves prescient or represents a potential concentration risk if healthcare valuations compress.

Looking Forward: What's Next for SCHD

The annual reconstitution cycle—a normal part of passive index management—will continue annually, ensuring the portfolio remains aligned with Schwab's dividend growth criteria. The success of this latest reshuffle will become apparent over the next 12-24 months as dividend growth rates materialize and the fund's total return performance unfolds.

For dividend investors seeking consistent income with growth potential, these changes strengthen SCHD's appeal. The fund's willingness to rotate holdings based on forward-looking dividend growth prospects, rather than simply clinging to household names, demonstrates a disciplined investment approach. Whether this reconstitution produces superior returns will depend on whether UnitedHealth and Abbott indeed deliver the dividend growth Schwab's methodology projected, and whether the increased healthcare weighting remains appropriate as market conditions evolve. The true test will come in comparing SCHD's income and total return performance against competing dividend-focused strategies over the coming years.